

**Methods.** Twenty-two veterans with a clinical *E. coli* isolate (11 FQ-resistant [FQ-R], 11 FQ-susceptible [FQ-S]) and their HH members underwent serial stool sampling (2–6 occasions each). Stool samples were cultured selectively for FQ-S and FQ-R *E. coli*. Per sample, 10 *E. coli* colonies underwent PCR-based profiling; one colony per profile underwent pulsotyping and PCR-based ST131 detection, as did all clinical isolates. Each strain's extent of within-HH sharing and colonization were calculated.

**Results.** Of the 11 FQ-R clinical isolates, seven were ST131 and four non-ST131; all FQ-S clinical isolates were non-ST131. The 22 HHs included 68 total subjects (49 humans, 19 pets), with a per-HH mean of three subjects, 9.5 total fecal samples, and 6.7 unique strains. The index patient's stool yielded the corresponding clinical strain in 91% of FQ-R HHs, but only 45% of FQ-S HHs. Sharing of the clinical strain occurred in 45% of FQ-R HHs (43% if ST131, 50% if non-ST131), vs. 27% of FQ-S HHs. For the 22 clinical strains, the extent of within-HH sharing and colonization was greater for FQ-R than FQ-S strains (sharing index, 0.45 vs. 0.15; colonization index, 0.47 vs. 0.14). The FQ-R HHs also yielded 12 additional (non-clinical) FQ-R strains, the FQ-S HHs only 1. Non-clinical FQ-R strains colonized much less extensively than FQ-R clinical strains and were not shared between HH members.

**Conclusion.** Compared with FQ-S clinical *E. coli*, FQ-R clinical *E. coli* more frequently colonize the index patient, are shared among HH members, and co-occur with other HH FQ-R strains, all of which may drive population-level resistance. Given the potentially important clinical implications of within-HH strain sharing and colonization, better understandings are needed of its mechanisms, including characteristics of the strain, host, and gut microbiota.

**Disclosures.** J. R. Johnson, Crucell/Janssen: Consultant, Consulting fee. Allergan: Grant Investigator, Research support. Merck: Grant Investigator, Research support. Melinta: Grant Investigator, Research support. Tetrphase: Grant Investigator, Research support. Syntiron: Consultant, Consulting fee.

#### 657. Epstein-Barr Virus Genetic Diversity in Blood vs. Saliva Samples From Patients with Infectious Mononucleosis

Mariana Abdulnoor, BSc<sup>1</sup>; Nasser Khodai-Booran, PhD<sup>1</sup>; Jessica Pietrzyk, BSc<sup>1</sup>; Tara Paton, PhD<sup>2</sup>; Guillermo Casallo, BSc<sup>2</sup> and Upton Allen, MD<sup>1</sup>; <sup>1</sup>Division of Infectious Diseases, Hospital for Sick Children, Toronto, ON, Canada, <sup>2</sup>Research Institute, Hospital for Sick Children, Toronto, ON, Canada

**Session:** 65. Pathogenesis and Immune Response  
*Thursday, October 4, 2018: 12:30 PM*

**Background.** The Epstein-Barr virus (EBV) is associated with several diseases, including infectious mononucleosis as well as malignant disorders. The relationship between strains of the virus and disease manifestation or illness severity is of interest. Such strains have been defined by genetic variations in the major viral genes. As a first step toward a better understanding of the relationship between strains and clinical outcomes, data are required on the patterns of genetic diversity of the virus in different populations. In this study, we examined the genetic diversity of the BZLF-1 gene, which is a major lytic gene of the virus.

**Methods.** We sequenced the BZLF-1 gene of EBV following amplification from DNA that was extracted from blood and saliva from previously healthy Canadian children and young adults with infectious mononucleosis. Sequencing was done by Sanger methodology (dideoxy DNA sequencing) and the sequences were aligned with a reference strain of EBV using Geneious software. The variant burden and types of single nucleotide variants were compared in blood and saliva samples.

**Results.** Twenty-six samples were obtained from 24 patients less than 24 years of age (16 saliva and 10 blood samples). Two subjects provided paired blood and saliva samples at the same visit. Among 36 single nucleotide variations (SNVs), 22% were common to both blood and saliva samples. There was a nonstatistically significant trend for more SNVs among blood compared with saliva samples (median 6 and 1, ranges 0–8 and 0–9, respectively). Of the 3 exons of BZLF-1, exon 1 had the greatest frequency of SNVs compared with exons 2 and 3. Among the paired samples of blood and saliva, there were different genetic variants of the BZLF-1 gene in the blood compared with the saliva samples obtained from patients with infectious mononucleosis.

**Conclusion.** Among patients with infectious mononucleosis, different genetic variants of EBV may be present in blood compared with saliva. Blood samples revealed viral strains with a tendency for more genetic diversity compared with saliva. The potential compartmentalization of strains is of relevance in sample selection for the evaluation of the potential clinical impact of the genetic diversity of EBV. In addition, the potential impact on disease pathogenesis is of interest.

**Disclosures.** All authors: No reported disclosures.

#### 658. Trends in Mumps Cases and Incidence, United States, January 2016–April 2018

Nakia Clemmons, MPH<sup>1</sup>; Adria Lee, MSPH<sup>2</sup>; Adriana S. Lopez, MHS<sup>3</sup>; Mariel Marlow, PhD<sup>4</sup>; Mona Marin, MD<sup>1</sup> and Manisha Patel, MD, MS<sup>1</sup>; <sup>1</sup>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, <sup>2</sup>Ihrc, Inc., Contracting Agency to the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, <sup>3</sup>Centers for Disease Control and Prevention, Atlanta, Georgia, <sup>4</sup>CDC, Atlanta, Georgia

**Session:** 66. Public Health: Epidemiology and Outbreaks  
*Thursday, October 4, 2018: 12:30 PM*

**Background.** Since 2012, there has been a steady increase in the number of reported mumps cases and outbreaks in the United States, primarily affecting young, two-dose vaccinated adults. We analyzed epidemiologic characteristics of mumps cases reported nationally from 2016 to 2018.

**Methods.** We included confirmed and probable mumps cases transmitted from January 2016 to April 2018 by 52 health department jurisdictions (50 states, DC and NYC) that report cases to the National Notifiable Diseases Surveillance System (NNDSS). We calculated overall and age-specific incidence rates (IR) by dividing the annual number of mumps cases by the corresponding US Census Bureau's Bridged Race population estimates. Cases were reported as outbreak-related or non-related in NNDSS by the submitting jurisdiction.

**Results.** Between January 1, 2016–April 21, 2018, 13,348 mumps cases ( $n = 6,369$  in 2016,  $n = 6,056$  in 2017 and  $n = 923$  in 2018) were reported to NNDSS. IRs were 20, 19, and 2.9/million population in 2016, 2017, and January–April 2018, respectively. Young adults (18–22 years) had the highest IR: 88, 76, and 7.3/million population in 2016, 2017, and 2018, respectively. During January–April timeframe, 348 more cases were reported in 2016 (IR = 3.8/million) and almost four times as many cases were reported in 2017 ( $n = 3,376$ , IR = 10.5/million) compared with 2018 ( $P < 0.0001$ ). The number of jurisdictions that reported cases in the first 4 months of each year was 39, 44, and 47 in 2016, 2017, and 2018, respectively. During the same timeframe, the number of outbreak-related cases reported was lower in 2018 ( $n = 523$ ) vs. 2017 ( $n = 2,350$ ) and 2016 ( $n = 1,271$ ) ( $P < 0.0001$ ), and the number of jurisdictions reporting outbreak-related cases was lower in 2018 ( $n = 16$ ) vs. 2017 ( $n = 32$ ,  $P = 0.002$ ) and 2016 ( $n = 22$ ,  $P = 0.23$ ).

**Conclusion.** Preliminary data suggest that the overall and outbreak-related mumps cases may be decreasing in 2018 after 2 years of increased reports. However, the number of jurisdictions reporting mumps cases has not decreased. Thorough investigations of sporadic cases may lead to improved identification of epidemiologic linkages and earlier identification of outbreaks.

**Disclosures.** All authors: No reported disclosures.

#### 659. Mumps Outbreak in a High School: Uptake and Parental Perceptions of Third Dose MMR Recommendations, Dallas County, Texas, 2017

Wendy Chung, MD, MS; Joel Henderson, MPH; Meredith Stocks, MPH; Folasuyi Richardson, MPH; Sonya Hughes, MPH and Michelle Ward, MPH; Acute Communicable Disease Epidemiology, Dallas County Department of Health and Human Services, Dallas, Texas

**Session:** 66. Public Health: Epidemiology and Outbreaks  
*Thursday, October 4, 2018: 12:30 PM*

**Background.** In February 2017, a mumps outbreak was identified in a large Dallas high school among students who had previously completed the two-dose MMR vaccination series. Early notification of recommendations for third dose MMR and free vaccination clinics provided an opportunity to assess vaccine uptake, efficacy, and parental perceptions of third dose MMR recommendations.

**Methods.** Mumps illnesses were classified as probable or confirmed cases using 2012 CSTE case definitions. Information about vaccination status, exposure history, and illness characteristics was collected from case interviews and medical records. A third MMR vaccine was recommended to all noncase students and offered without charge at school-based vaccination clinics. Supplemental questionnaires assessing parental knowledge and attitudes regarding this third MMR recommendation were administered to guardians of a randomly selected sample of 20 students who received third dose MMR and 50 students who did not receive the vaccine. Fishers exact tests and chi-square were used to compare responses. Data analysis was performed using SAS 9.4.

**Results.** From February to May 2017, 28 PCR-confirmed and 12 probable mumps cases were identified in students attending one high school campus (24.3 cases per 1,000 students). Of the 1,646 enrolled students, 99.8% had documentation of at least two doses of MMR prior to the outbreak, including all mumps cases. Three undervaccinated students who declined to receive one dose of MMR were excluded from school during the outbreak. Following public health recommendations for a voluntary third MMR dose, 291 students (17.6%) elected to receive a third MMR. No mumps cases occurred in students who received a third vaccine dose. Parental perception of protective benefit of an additional third dose of MMR was significantly associated with decisions to receive third dose MMR (OR: 4.9; 95% CI = 1.6–15.3).

**Conclusion.** Responsiveness to health department recommendations for third MMR vaccination in this outbreak setting was limited, even with broad educational communications and free school-based vaccine clinics. The challenges in achieving robust voluntary uptake of a third MMR dose may not improve substantially despite recent ACIP recommendations, in the absence of school mandates requiring third dose of MMR during outbreaks.

**Disclosures.** All authors: No reported disclosures.

#### 660. Are US Clinicians Thinking Measles in the Post-elimination Era? Surveillance for Measles-Like Illness in a Commercially Insured US Population

Susannah McKay, PhD, MPH<sup>1</sup>; Jessica Leung, MPH<sup>2</sup>; Paul Gastanaduy, MD, MPH<sup>2</sup>; Janell Routh, MD, MHS<sup>2</sup> and Rafael Harpaz, MD, MPH<sup>2</sup>; <sup>1</sup>Epidemic Intelligence Service, Center for Surveillance, Epidemiology and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia, <sup>2</sup>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

**Session:** 66. Public Health: Epidemiology and Outbreaks  
*Thursday, October 4, 2018: 12:30 PM*

**Background.** In September 2016, the Americas was the first region to eliminate measles, a highly contagious, vaccine-preventable disease that can lead to complications and death. To maintain elimination, the Pan American Health Organization (PAHO) suggested a minimum rate of suspected measles investigations ( $\geq 2$  per 100,000 population) be conducted annually. However, measles-like illness (MLI) investigations conducted by US clinicians are not tracked by the measles surveillance program in the

United States. To ensure the US meets PAHO standards, we estimated the rate of MLI investigations using a large insurance claims database.

**Methods.** We used the 2009–2016 Truven Health MarketScan<sup>®</sup> Databases to identify MLI and MLI investigations. MLI were defined using International Classification of Diseases (ICD)-9/10 diagnostic codes in two ways: *a priori*, using the Council of State and Territorial Epidemiologists (CSTE) measles case definition or empirically, using ICD codes on insurance claims with a measles diagnostic code. MLI investigations were defined as MLI occurring up to 5 days prior to a measles diagnostic code or billing code for measles serology testing. We computed annual rates of MLI investigations per 100,000 population.

**Results.** We identified ~35.5 million MLI using the *a priori* definition. Of these, 24,010 had a measles serology code within 5 days; median age was 30 and 51% were aged 18–34 years. Using the empirical definition we identified ~46 million MLI. Of these, 29,940 were coupled with a measles serology code; median age was 31 and 50% were aged 18–34 years. The median annual rates for MLI investigations were 3.2 (*a priori*) and 4.3 (empirical) per 100,000 population.

**Conclusion.** Maintaining measles elimination requires continued vigilance by clinicians and high-quality case-based surveillance. The estimated rates of MLI investigations in this US population exceeded the PAHO standard, suggesting that the quality of US measles surveillance is robust.

**Disclosures.** All authors: No reported disclosures.

### 661. Surveillance of Rabies Prophylactic Treatments After Exposure to Animals: 5 Years Experience

Georgios Dougas, DVM<sup>1</sup>; Vasileia Konte, MD, MSc<sup>1</sup>; Konstantinos Mitrou, RN, MSc<sup>1</sup>; Emmanouel Christodoulou, MD<sup>2</sup>; Michail Stavrakakis, DVM<sup>2</sup>; Agoritsa Baka, MD<sup>1</sup>; Theano Georgakopoulou, MD, MSc, MPH, PhD<sup>1</sup>; Symeon Metallidis, MD, PhD<sup>3</sup>; Ioannis Istikoglou, RN, MSc<sup>4</sup>; Chrysa Pargiana, MD<sup>5</sup>; Aikaterini Liona, Adm.<sup>1</sup>; Foteini Tsalikoglou, MD, MSc<sup>6</sup>; Myrsini Tzani, DVM, MSc<sup>7</sup>; Marilina Korou, DVM, MSc, PhD<sup>7</sup>; Konstantia Tasioudi, DVM, MSc, PhD<sup>8</sup>; Maria Mavrouli, Biologist, MSc, PhD<sup>9</sup>; Georgia Vrioni, MD, PhD<sup>9</sup> and Sotirios Tsiodras, MD, MSc, PhD, FIDSA<sup>10</sup>.  
<sup>1</sup>Hellenic Center for Disease Control and Prevention, Athens, Greece, <sup>2</sup>Department of Internal Medicine, Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece, <sup>3</sup>Internal Medicine Department, Infectious Diseases Division, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, <sup>4</sup>Infection Control Committee, "AHEPA" University Hospital, Thessaloniki, Greece, <sup>5</sup>Infectious Diseases Hospital of Thessaloniki, Thessaloniki, Greece, <sup>6</sup>Ministry of Health, ATHENS, Greece, <sup>7</sup>Department of Zoonoses, Animal Health Directorate, Directorate General of Veterinary Services, Ministry of Rural Development and Food, Athens, Greece, <sup>8</sup>Virology Laboratory – National Reference Laboratory for Rabies in animals, Department of Molecular Diagnostics, FMD, Virological, Rickettsial & Exotic Diseases, Athens Veterinary Center, Ministry of Rural Development and Food, Athens, Greece, <sup>9</sup>Department of Microbiology, Medical School, University of Athens, Athens, Greece, <sup>10</sup>National and Kapodistrian University of Athens Medical School, Athens, Greece

**Session:** 66. Public Health: Epidemiology and Outbreaks


**Thursday, October 4, 2018: 12:30 PM**

**Background.** Rabies re-emerged in Greek fauna in October 2012, 25 years after the last report in animals. Hellenic Center for Disease Control & Prevention developed a semi-active surveillance system to monitor the medical management of potentially exposed persons to rabies. This study aims to providing insight on the biologicals administered and the epidemiological characteristics of the cases where post-exposure prophylaxis was initiated after contact with animals.

**Methods.** Data received from November 2012 to December 2017 on demographics, exposure event, animal species involved, category of exposure (COE) according to WHO, vaccination history, the veterinary evaluation of the animal and the type of treatment administered, were analyzed with Epidata Analysis V.2.2.2.180.

**Results.** A total of 1,616 cases (63.2% males) received rabies post-exposure prophylaxis. In 94.7% of cases cleansing of the wound before visiting a medical practitioner took place during the first 3 hours after the exposure whereas 75.1% of victims presented at a healthcare setting during the first 24 hours; COE III cases had shorter time interval ( $P < 0.01$ ), before arrival at a hospital (mdn = 1.3 hours) compared with COE II (mdn = 3.6 hours) or COE I (mdn = 88.2 hours) (Figure 1);

Figure 1. Time elapsed from exposure until presentation to a hospital by WHO category of exposure, boxplot diagram, Greece 2012–2017



55.1% were initiated on a vaccine series, 43.1% received both vaccine and immunoglobulin and 1.7% immunoglobulin alone. Exposure to stray dogs represented 67.3% of all incidents (Table 1).

**Table 1:** Post-Exposure Prophylaxis (PEP) by Animal Involved, Greece, 2012–2017

Species	Status	PEP	%
Dog	Ownerless	1,087	67.3
	With owner	252	15.6
	Unknown	20	1.2
Cat	Ownerless	120	7.4
	Companion	17	1.1
	Unknown	1	0.1
Fox		48	3.0
Bat		33	2.0
Other domestic species		6	0.4
Other wildlife species		18	1.1
Unidentified		14	0.9
Total		1,616	100

No human case was recorded.

**Conclusion.** The vast majority of the reported treatments involved stray dogs as Greek legislation permits free roaming of ownerless companion animals in urban settings. Bat was the fourth most frequently reported species in our treatment series. Surveillance of post-exposure prophylaxis represents a valuable tool for outlining the epidemiological profile of treated cases and for planning of effective policies for the management of rabies.

**Disclosures.** All authors: No reported disclosures.

### 662. Tick Borne-Associated Thrombocytopenia Among United States Veterans in Long Island New York

Olga Kaplun, MD<sup>1</sup>; Beth Lemaitre, MT<sup>2</sup>; Zeena Lobo, MD<sup>3</sup> and George Pseudos Jr., MD<sup>4</sup>; <sup>1</sup>Infectious Diseases, Stony Brook University Hospital, Stony Brook, New York, <sup>2</sup>Microbiology/Pathology, Northport Veterans Affairs Medical Center, Northport, New York, <sup>3</sup>Infectious Disease, Veterans Affairs Medical Center, Northport, New York, <sup>4</sup>Infectious Diseases, Northport Veterans Affairs Medical Center, Northport, New York

**Session:** 66. Public Health: Epidemiology and Outbreaks

**Thursday, October 4, 2018: 12:30 PM**

**Background.** Long Island, New York, is highly endemic for tick borne illnesses (TBI) with rising numbers of cases in the past years. Thrombocytopenia is a known complication of babesiosis caused by *Babesia microti*, anaplasmosis caused by *Anaplasma phagocytophilum*, and ehrlichiosis caused by *Ehrlichia chaffeensis*. We identified cases of thrombocytopenia attributed to TBI in our institution.

**Methods.** Retrospective chart review of patients diagnosed with babesiosis, anaplasmosis, and ehrlichiosis from 2000 to 2017 at Northport Veterans Affairs Medical Center. Demographics, method of diagnosis (PCR/serologies), CBC/chemistries, treatment choices, and outcomes were analyzed.

**Results.** Thirty-two veterans (VETS) were identified with the following TBI: Babesiosis 22, Ehrlichiosis 6, Anaplasmosis 4. The majority of cases (19) were from Suffolk County, Long Island. The median (MED) age of this group was 62 years (range 31–89). Ninety-one percent were Caucasian, 9% Black. 37.5% had history of tick bite. The MED temperature on presentation was 101.9°F (range 97.6–105.2°F). 56% had HTN, 6% DM, 37% HLD, 9% hepatitis C, 3% HIV. Laboratory studies: MED platelet count 88,000/μL (36,000–161,000); MED hemoglobin 12 gm/dL (5.6–15.6); MED ALT 41 IU/L (6–330); MED LDH 335 IU/L (193–1,322). Twelve VETS had positive C6 peptide. The peak MED *B. microti* parasitemia was 1.4% (0.1–3%). PCR tests were available in the later years of the study period: three were positive for *E. chaffeensis*, two for *A. phagocytophilum*, and 14 for *B. microti*. The majority of the cases (19) were observed after year 2010. Morulae were seen in only one case. Haptoglobin in eight VETS was undetectable. One veteran with history of splenectomy and babesiosis with 3% parasitemia required exchange transfusion with 12 units of PRBCs. Two other babesiosis cases required regular transfusion of PRBCs. 20 babesiosis cases were treated with azithromycin-atovaquone and two with clindamycin-primaquine. Doxycycline was used in the other cases. One patient developed NSTEMI and required coronary stent placement. Platelet counts returned to baseline levels with treatment. No deaths occurred.

**Conclusion.** The incidence of TBI in Long Island, New York is rising. PCR testing for TBI can be utilized in our VETS presenting with febrile illness and thrombocytopenia to help identify the possible tick borne pathogen during the months of high tick activity.

**Disclosures.** All authors: No reported disclosures.

### 663. Characteristics, Treatment Patterns, and Outcomes of Outpatients With Rickettsial Diseases in a Large, Commercially Insured Population: United States, 2005–2016

Alison Binder, MS; Amy E. Peterson, DVM, PhD and Paige Armstrong, MD MHS; Rickettsial Zoonoses Branch, Centers for Disease Control and Prevention, Atlanta, Georgia

**Session:** 66. Public Health: Epidemiology and Outbreaks

**Thursday, October 4, 2018: 12:30 PM**